Last reviewed 2026-05-23 · How we verify

Pyrazapon (RIPAZEPAM)

Phase 2 active Small molecule ✓ Verified May 2026

Pyrazapon (generic name: RIPAZEPAM) is a ripazepam drug. It is currently in Phase 2 development.

Ripazepam is thought to work by modulating the activity of GABA receptors in the brain.

Pyrazapon is a small molecule. It is also known by the synonyms CL-683 and Ripazepam.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	RIPAZEPAM
Drug class	ripazepam
Target	GABA-A receptor; anion channel
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is like a busy city with many different neighborhoods. GABA receptors are like the traffic lights that help control the flow of information between these neighborhoods. Ripazepam is believed to affect how these traffic lights work, which can help calm down overactive brain activity.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pyrazapon CI brief — competitive landscape report
Pyrazapon updates RSS · CI watch RSS

Frequently asked questions about Pyrazapon

What is Pyrazapon?

Pyrazapon (RIPAZEPAM) is a ripazepam drug.

How does Pyrazapon work?

Ripazepam is thought to work by modulating the activity of GABA receptors in the brain.

What is the generic name of Pyrazapon?

RIPAZEPAM is the generic (nonproprietary) name of Pyrazapon.

What drug class is Pyrazapon in?

Pyrazapon belongs to the ripazepam class. See all ripazepam drugs at /class/ripazepam.

What development phase is Pyrazapon in?

Pyrazapon is in Phase 2.

What does Pyrazapon target?

Pyrazapon targets GABA-A receptor; anion channel and is a ripazepam.

Drug class: All ripazepam drugs
Target: All drugs targeting GABA-A receptor; anion channel
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing